for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Denali Therapeutics Inc

DNLI.OQ

Latest Trade

15.17USD

Change

0.77(+5.35%)

Volume

122,696

Today's Range

14.53

 - 

15.35

52 Week Range

13.78

 - 

28.84

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Denali Therapeutics Inc Reports Quarterly Loss Per Share Of $0.61

Aug 6 (Reuters) - Denali Therapeutics Inc <DNLI.O>::DENALI THERAPEUTICS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.DENALI THERAPEUTICS - COLLABORATION REVENUE WAS $4.2 MILLION FOR 3 MONTHS ENDED JUNE 30, 2019, VERSUS COLLABORATION REVENUE OF $1.6 MILLION FOR 3 MONTHS ENDED JUNE 30, 2018.CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES WERE $534.4 MILLION AS OF JUNE 30, 2019.QTRLY LOSS PER SHARE $0.61.Q2 EARNINGS PER SHARE VIEW $-0.46, REVENUE VIEW $3.9 MILLION -- REFINITIV IBES DATA.

Denali Therapeutics Receives Orphan Drug And Rare Pediatric Disease Designation For Dnl310

June 11 (Reuters) - Denali Therapeutics Inc <DNLI.O>::DENALI THERAPEUTICS RECEIVES ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATION FOR DNL310, AND EXPANDS ITS PORTFOLIO OF BRAIN PENETRANT ENZYME REPLACEMENT PROGRAMS.DENALI THERAPEUTICS INC - DNL310 ON TRACK TO ENTER PHASE 1/2 CLINICAL STUDY IN HUNTER SYNDROME PATIENTS IN 2020.DENALI THERAPEUTICS - BASED ON PRE-CLINICAL PROOF OF CONCEPT WITH DNL310, CO INITIATED TWO ADDITIONAL ERT PROGRAMS THAT ARE ENABLED BY TV TECHNOLOGY..

Denali Therapeutics Says Collaboration Revenue Was $4.2 Mln For Three Months Ended March 31, 2019

May 8 (Reuters) - Denali Therapeutics Inc <DNLI.O>::DENALI THERAPEUTICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.DENALI THERAPEUTICS - COLLABORATION REVENUE WAS $4.2 MILLION FOR 3 MONTHS ENDED MARCH 31, 2019, VERSUS $0.6 MILLION FOR 3 MONTHS ENDED MARCH 31, 2018.COLLABORATION REVENUE WAS $4.2 MILLION FOR THREE MONTHS ENDED MARCH 31, 2019.CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES WERE $583.0 MILLION AS OF MARCH 31, 2019..QTRLY LOSS PER SHARE $0.41.Q2 EARNINGS PER SHARE VIEW $-0.46, REVENUE VIEW $3.9 MILLION -- REFINITIV IBES DATA.

Denali Therapeutics Inc Reports Q4 EPS Of $0.79

March 12 (Reuters) - Denali Therapeutics Inc <DNLI.O>::DENALI THERAPEUTICS REPORTS FULL YEAR 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.DENALI THERAPEUTICS INC QTRLY NET INCOME OF $77.5 MILLION COMPARED WITH NET LOSS FOR Q4 DECEMBER 31, 2017 OF $22.9 MILLION.DENALI THERAPEUTICS INC - CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES WERE $612.2 MILLION AS OF DECEMBER 31, 2018.DENALI THERAPEUTICS INC QTRLY EARNINGS PER SHARE $0.79.

Abcellera And Denali Therapeutics Sign Expanded Multi-Year, Multi-Target

Feb 28 (Reuters) - AbCellera::ABCELLERA AND DENALI THERAPEUTICS SIGN EXPANDED MULTI-YEAR, MULTI-TARGET DEAL TO DISCOVER THERAPEUTIC ANTIBODIES FOR NEUROLOGICAL DISEASES.ABCELLERA SAYS WILL RECEIVE A TECHNOLOGY ACCESS FEE AND RESEARCH FUNDING.ABCELLERA SAYS IS ELIGIBLE FOR MILESTONE PAYMENTS AND ROYALTIES BASED ON DEVELOPMENT AND COMMERCIALIZATION OF ANTIBODIES.

Sirion Biotech & Denali Therapeutics Join Forces To Develop Gene Therapies For Diseases Of Central Nervous System

Jan 9 (Reuters) - :SIRION BIOTECH AND DENALI THERAPEUTICS JOIN FORCES TO DEVELOP GENE THERAPIES FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM.SIRION - TERMS OF AGREEMENT INCLUDE DEVELOPMENT EXPENSES, UPFRONT, CONTINGENT MILESTONE PAYMENTS TO CO, LOW-TO-MID SINGLE DIGIT ROYALTIES ON NET SALES .

Denali Therapeutics Announces Positive Clinical Results With Its Lead RIPK1 Inhibitor Molecule

Nov 19 (Reuters) - Denali Therapeutics Inc <DNLI.O>::DENALI THERAPEUTICS ANNOUNCES POSITIVE CLINICAL RESULTS WITH ITS LEAD RIPK1 INHIBITOR MOLECULE AND INTENTION TO INITIATE PATIENT STUDIES IN MULTIPLE INDICATIONS IN COLLABORATION WITH SANOFI.DENALI THERAPEUTICS INC - DENALI AND PARTNER SANOFI PLAN TO EVALUATE DNL747 IN CLINICAL STUDIES FOR ALZHEIMER'S DISEASE.DENALI THERAPEUTICS INC - DENALI AND PARTNER SANOFI PLAN TO EVALUATE DNL747 IN CLINICAL STUDIES FOR ALS AND MULTIPLE SCLEROSIS (MS).DENALI THERAPEUTICS INC - PHASE 1 HEALTHY VOLUNTEER STUDY OF DNL747 MEETS ALL ENDPOINTS.DENALI THERAPEUTICS INC - IN ADDITION TO DNL747, SANOFI AND DENALI ARE PURSUING SEVERAL OTHER COMPOUNDS, INCLUDING DNL758.DENALI THERAPEUTICS INC - SANOFI INTENDS TO INITIATE CLINICAL TRIALS WITH DNL758 IN 2019..

Denali Therapeutics Inc Reports Q3 Loss Per Share Of $0.38

Nov 8 (Reuters) - Denali Therapeutics Inc <DNLI.O>::DENALI THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS AND ANNOUNCES THE APPOINTMENT OF JENNIFER COOK TO BOARD OF DIRECTORS.DENALI THERAPEUTICS INC QTRLY COLLABORATION REVENUE WAS $1.2 MILLION.DENALI THERAPEUTICS INC QTRLY LOSS PER SHARE $0.38.

Denali & Sanofi To Jointly Develop RIPK1 Inhibitors

Nov 1 (Reuters) - Denali Therapeutics Inc <DNLI.O>::DENALI THERAPEUTICS ANNOUNCES BROAD COLLABORATION WITH SANOFI TO DEVELOP RIPK1 INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL AND INFLAMMATORY DISEASES.TO RECEIVE $125 MILLION UPFRONT PAYMENT AND FUTURE MILESTONE PAYMENTS THAT COULD EXCEED $1 BILLION.DENALI - PLAN TO JOINTLY DEVELOP,COMMERCIALIZE PROGRAMS FOR NEUROLOGICAL INDICATIONS;SANOFI WILL DO THE SAME FOR SYSTEMIC INFLAMMATORY INDICATIONS.TWO LEAD MOLECULES DNL747 AND DNL758 TARGET A CRITICAL SIGNALING IN TNF RECEPTOR PATHWAY.DENALI - WILL SHARE PROFITS FROM DNL747 IN U.S., CHINA EQUALLY;WILL RECEIVE ROYALTY FROM SANOFI FOR OTHER TERRITORIES FOR DNL747, WORLDWIDE FOR DNL758.PHASE 3 TRIALS FOR ALL NEUROLOGICAL INDICATIONS WILL BE JOINTLY FUNDED BY SANOFI (70%) AND DENALI (30%).SANOFI WILL FULLY FUND CLINICAL DEVELOPMENT COSTS FOR DNL758 IN SYSTEMIC INFLAMMATORY DISEASES..

Denali Therapeutics Inc - QTRLY Loss Per Share $0.59

Denali Therapeutics Inc <DNLI.O>::DENALI THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.DENALI THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.59.DENALI THERAPEUTICS - COLLABORATION REVENUE WAS $1.6 MILLION FOR THREE MONTHS ENDED JUNE 30, 2018, WITH NO COLLABORATION REVENUE RECOGNIZED YEAR AGO QUARTER.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up